277 related articles for article (PubMed ID: 15641142)
21. Pituitary adenylate cyclase-activating peptide stimulates cyclic AMP accumulation in UMR 106 osteoblast-like cells.
Kovacs CS; Chik CL; Li B; Karpinski E; Ho AK
J Endocrinol; 1996 May; 149(2):287-95. PubMed ID: 8708540
[TBL] [Abstract][Full Text] [Related]
22. Pituitary adenylate cyclase-activating polypeptide receptors mediating insulin secretion in rodent pancreatic islets are coupled to adenylate cyclase but not to PLC.
Jamen F; Puech R; Bockaert J; Brabet P; Bertrand G
Endocrinology; 2002 Apr; 143(4):1253-9. PubMed ID: 11897681
[TBL] [Abstract][Full Text] [Related]
23. Characterization of a guanosine-nucleotide-binding-protein-coupled receptor for pituitary adenylate-cyclase-activating polypeptide on plasma membranes from rat brain.
Schäfer H; Schwarzhoff R; Creutzfeldt W; Schmidt WE
Eur J Biochem; 1991 Dec; 202(3):951-8. PubMed ID: 1662620
[TBL] [Abstract][Full Text] [Related]
24. Interaction of ovine pituitary adenylate cyclase-activating peptide (PACAP-38) with rat lung membranes.
Bitar KG; Coy DH
Peptides; 1993; 14(3):621-7. PubMed ID: 8392724
[TBL] [Abstract][Full Text] [Related]
25. Presence of highly selective receptors for PACAP (pituitary adenylate cyclase activating peptide) in membranes from the rat pancreatic acinar cell line AR 4-2J.
Buscail L; Gourlet P; Cauvin A; De Neef P; Gossen D; Arimura A; Miyata A; Coy DH; Robberecht P; Christophe J
FEBS Lett; 1990 Mar; 262(1):77-81. PubMed ID: 2156735
[TBL] [Abstract][Full Text] [Related]
26. VPAC2 receptors mediate vasoactive intestinal peptide-induced neuroprotection against neonatal excitotoxic brain lesions in mice.
Rangon CM; Goursaud S; Medja F; Lelièvre V; Mounien L; Husson I; Brabet P; Jégou S; Janet T; Gressens P
J Pharmacol Exp Ther; 2005 Aug; 314(2):745-52. PubMed ID: 15872042
[TBL] [Abstract][Full Text] [Related]
27. Vasoactive intestinal peptide and pituitary adenylate cyclase activating polypeptide stimulate interleukin-6 production in prostate cancer cells and prostatic epithelial cells.
Nagakawa O; Junicho A; Akashi T; Koizumi K; Matsuda T; Fuse H; Saiki I
Oncol Rep; 2005 Jun; 13(6):1217-21. PubMed ID: 15870945
[TBL] [Abstract][Full Text] [Related]
28. Comparative effects of PACAP and VIP on pancreatic endocrine secretions and vascular resistance in rat.
Bertrand G; Puech R; Maisonnasse Y; Bockaert J; Loubatières-Mariani MM
Br J Pharmacol; 1996 Feb; 117(4):764-70. PubMed ID: 8646426
[TBL] [Abstract][Full Text] [Related]
29. Regulation of the rat proopiomelanocortin gene expression in AtT-20 cells. II: Effects of the pituitary adenylate cyclase-activating polypeptide and vasoactive intestinal polypeptide.
Aoki Y; Iwasaki Y; Katahira M; Oiso Y; Saito H
Endocrinology; 1997 May; 138(5):1930-4. PubMed ID: 9112389
[TBL] [Abstract][Full Text] [Related]
30. Receptors for VIP and PACAP in guinea pig cerebral cortex: effects on cyclic AMP synthesis and characterization by 125I-VIP binding.
Zawilska JB; Dejda A; Niewiadomski P; Gozes I; Nowak JZ
J Mol Neurosci; 2005; 25(3):215-24. PubMed ID: 15800375
[TBL] [Abstract][Full Text] [Related]
31. Regulation of growth hormone release in common carp pituitary cells by pituitary adenylate cyclase-activating polypeptide: signal transduction involves cAMP- and calcium-dependent mechanisms.
Xiao D; Chu MM; Lee EK; Lin HR; Wong AO
Neuroendocrinology; 2002 Nov; 76(5):325-38. PubMed ID: 12457043
[TBL] [Abstract][Full Text] [Related]
32. Pituitary adenylate cyclase-activating polypeptide (PACAP) stimulates exocrine pancreas in conscious preruminating calves.
Zabielski R; Onaga T; Mineo H; Okine E; Kato S
Comp Biochem Physiol C Pharmacol Toxicol Endocrinol; 1994 Sep; 109(1):93-9. PubMed ID: 7881813
[TBL] [Abstract][Full Text] [Related]
33. Vasoactive intestinal peptide (VIP)/pituitary adenylate cyclase-activating peptide receptor subtypes in mouse calvarial osteoblasts: presence of VIP-2 receptors and differentiation-induced expression of VIP-1 receptors.
Lundberg P; Lundgren I; Mukohyama H; Lehenkari PP; Horton MA; Lerner UH
Endocrinology; 2001 Jan; 142(1):339-47. PubMed ID: 11145597
[TBL] [Abstract][Full Text] [Related]
34. Receptors for vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide in the goose cerebral cortex.
Zawilska JB; Niewiadomski P; Nowak JZ
Pol J Pharmacol; 2004; 56(2):203-11. PubMed ID: 15156071
[TBL] [Abstract][Full Text] [Related]
35. PACAPs stimulate duodenal bicarbonate secretion at PACAP receptors in the rat.
Takeuchi K; Takehara K; Kato S; Yagi K
Am J Physiol; 1997 Mar; 272(3 Pt 1):G646-53. PubMed ID: 9124587
[TBL] [Abstract][Full Text] [Related]
36. Effect of vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide on pancreatic, hepatic and duodenal mucosal bicarbonate secretion in the pig.
Glad H; Ainsworth MA; Svendsen P; Fahrenkrug J; Schaffalitzky de Muckadell OB
Digestion; 2003; 67(1-2):56-66. PubMed ID: 12743442
[TBL] [Abstract][Full Text] [Related]
37. Recognition of pituitary adenylate cyclase-activating polypeptide/vasoactive intestinal polypeptide (PACAP/VIP) hybrids and related peptides by rat brain membranes.
Ando E; Nokihara K; Naruse S; Wray V
Biomed Pept Proteins Nucleic Acids; 1996; 2(2):41-6. PubMed ID: 9346825
[TBL] [Abstract][Full Text] [Related]
38. Peptidergic activation of transcription and secretion in chromaffin cells. Cis and trans signaling determinants of pituitary adenylyl cyclase-activating polypeptide (PACAP).
Taupenot L; Mahata SK; Wu H; O'Connor DT
J Clin Invest; 1998 Feb; 101(4):863-76. PubMed ID: 9466982
[TBL] [Abstract][Full Text] [Related]
39. PACAP deficient mice display reduced carbohydrate intake and PACAP activates NPY-containing neurons in the rat hypothalamic arcuate nucleus.
Nakata M; Kohno D; Shintani N; Nemoto Y; Hashimoto H; Baba A; Yada T
Neurosci Lett; 2004 Nov; 370(2-3):252-6. PubMed ID: 15488333
[TBL] [Abstract][Full Text] [Related]
40. Receptor occupancy and adenylate cyclase activation in AR 4-2J rat pancreatic acinar cell membranes by analogs of pituitary adenylate cyclase-activating peptides amino-terminally shortened or modified at position 1, 2, 3, 20, or 21.
Robberecht P; Gourlet P; De Neef P; Woussen-Colle MC; Vandermeers-Piret MC; Vandermeers A; Christophe J
Mol Pharmacol; 1992 Aug; 42(2):347-55. PubMed ID: 1325033
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
